Blood / Hematology » ARYx Therapeutics Announces Results...
Home » News » ARYx Therapeutics Announces Results Of...
ARYx Therapeutics Announces Results Of Phase 2/3 Clinical Trial On Anticoagulant Agent Tecarfarin
ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced results from its Phase 2/3 clinical trial, EmbraceAC, comparing its novel anticoagulant agent tecarfarin (previously ATI-5923) with the leading oral anticoagulant warfarin.
Read full article @ MedicalNewsToday
Read Also Other "Blood / Hematology" News
-
Ablynx Announces Positive Phase I Results For Subcutaneous Administration Of Its Anti-Thrombotic Nanobody(R) (Alx-0681)
Ablynx [Euronext Brussels: ABLX] announced the positive results from its...